{ "cik": 744218, "cik_padded": "0000744218", "entityName": "Celldex Therapeutics, Inc.", "fiscal_years": [ { "accn": "0001104659-26-019652", "filed": "2026-02-25", "fiscal_year": 2025, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 2714000.0, "cash": 28871000.0, "eps_diluted": -3.9, "free_cash_flow": -213659000.0, "net_income": -258757000.0, "operating_cash_flow": -210945000.0, "operating_income": -287367000.0, "revenue": 1545000.0, "stockholders_equity": 527165000.0, "total_assets": 582983000.0, "total_liabilities": 55818000.0 }, "period_end": "2025-12-31", "ratio_units": { "leverage": "ratio", "revenue_growth_yoy": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 0.10588335720315271, "revenue_growth_yoy": -0.7799145299145299, "roa_avg2y": -0.37628542531463516, "roa_period_end": -0.44384999219531274, "roe_avg2y": -0.40615773405432554, "roe_period_end": -0.49084631946354557 } }, { "accn": "0001104659-26-019652", "filed": "2026-02-25", "fiscal_year": 2024, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 1919000.0, "cash": 28356000.0, "eps_diluted": -2.45, "free_cash_flow": -159697000.0, "net_income": -157863000.0, "operating_cash_flow": -157778000.0, "operating_income": -195078000.0, "revenue": 7020000.0, "stockholders_equity": 747005000.0, "total_assets": 792340000.0, "total_liabilities": 45335000.0 }, "period_end": "2024-12-31", "ratio_units": { "leverage": "ratio", "revenue_growth_yoy": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 0.06068901814579555, "revenue_growth_yoy": 0.019904111579253234, "roa_avg2y": -0.250981146564258, "roa_period_end": -0.19923643890249135, "roe_avg2y": -0.26843431595271455, "roe_period_end": -0.21132790275834837 } }, { "accn": "0001410578-25-000216", "filed": "2026-02-25", "fiscal_year": 2023, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "net_income": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 1818000.0, "cash": 34814000.0, "eps_diluted": -2.92, "free_cash_flow": -109109000.0, "net_income": -141429000.0, "operating_cash_flow": -107291000.0, "operating_income": -154542000.0, "revenue": 6883000.0, "stockholders_equity": 429171000.0, "total_assets": 465627000.0, "total_liabilities": 36456000.0 }, "period_end": "2023-12-31", "ratio_units": { "leverage": "ratio", "revenue_growth_yoy": "ratio", "roa_avg2y": "ratio", "roa_period_end": "ratio", "roe_avg2y": "ratio", "roe_period_end": "ratio" }, "ratios": { "leverage": 0.08494516171875546, "revenue_growth_yoy": 1.9202375901569793, "roa_avg2y": -0.3456392158971213, "roa_period_end": -0.30373882957818166, "roe_avg2y": -0.37446036736720173, "roe_period_end": -0.32953997357696585 } }, { "accn": "0001410578-24-000076", "filed": "2026-02-25", "fiscal_year": 2022, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 1828000.0, "cash": 29429000.0, "eps_diluted": -2.4, "free_cash_flow": -105560000.0, "operating_cash_flow": -103732000.0, "operating_income": -115234000.0, "revenue": 2357000.0, "stockholders_equity": 326204000.0, "total_assets": 352735000.0, "total_liabilities": 26531000.0 }, "period_end": "2022-12-31", "ratio_units": { "leverage": "ratio", "revenue_growth_yoy": "ratio" }, "ratios": { "leverage": 0.08133254037350861, "revenue_growth_yoy": -0.4932272629542034 } }, { "accn": "0001410578-25-000216", "filed": "2025-02-27", "fiscal_year": 2021, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 1249000.0, "cash": 39143000.0, "eps_diluted": -1.64, "free_cash_flow": -62158000.0, "operating_cash_flow": -60909000.0, "operating_income": -71243000.0, "revenue": 4651000.0, "stockholders_equity": 419476000.0, "total_assets": 444654000.0, "total_liabilities": 25178000.0 }, "period_end": "2021-12-31", "ratio_units": { "leverage": "ratio", "revenue_growth_yoy": "ratio" }, "ratios": { "leverage": 0.06002250426722864, "revenue_growth_yoy": -0.3730115934214074 } }, { "accn": "0001410578-24-000076", "filed": "2024-02-26", "fiscal_year": 2020, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 1552000.0, "cash": 43836000.0, "eps_diluted": -2.02, "free_cash_flow": -41956000.0, "operating_cash_flow": -40404000.0, "operating_income": -63354000.0, "revenue": 7418000.0, "stockholders_equity": 209357000.0, "total_assets": 235838000.0, "total_liabilities": 26481000.0 }, "period_end": "2020-12-31", "ratio_units": { "leverage": "ratio", "revenue_growth_yoy": "ratio" }, "ratios": { "leverage": 0.1264872920418233, "revenue_growth_yoy": 1.0761265043380912 } }, { "accn": "0001104659-23-026701", "filed": "2023-02-28", "fiscal_year": 2019, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "eps_diluted": "USD/shares", "free_cash_flow": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 731000.0, "cash": 11232000.0, "eps_diluted": -3.51, "free_cash_flow": -47146000.0, "operating_cash_flow": -46415000.0, "operating_income": -55031000.0, "revenue": 3573000.0, "stockholders_equity": 94026000.0, "total_assets": 122933000.0, "total_liabilities": 28907000.0 }, "period_end": "2019-12-31", "ratio_units": { "leverage": "ratio", "revenue_growth_yoy": "ratio" }, "ratios": { "leverage": 0.3074362410397124, "revenue_growth_yoy": -0.6253931641853638 } }, { "accn": "0001104659-22-028070", "filed": "2022-02-28", "fiscal_year": 2018, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "free_cash_flow": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 813000.0, "cash": 24310000.0, "free_cash_flow": -76048000.0, "operating_cash_flow": -75235000.0, "operating_income": -156436000.0, "revenue": 9538000.0, "stockholders_equity": 124060000.0, "total_assets": 155809000.0, "total_liabilities": 31749000.0 }, "period_end": "2018-12-31", "ratio_units": { "leverage": "ratio", "revenue_growth_yoy": "ratio" }, "ratios": { "leverage": 0.25591649201999034, "revenue_growth_yoy": -0.25151063328886447 } }, { "accn": "0001104659-21-043161", "filed": "2021-03-29", "fiscal_year": 2017, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "free_cash_flow": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 1788000.0, "cash": 40288000.0, "free_cash_flow": -101719000.0, "operating_cash_flow": -99931000.0, "operating_income": -121527000.0, "revenue": 12743000.0, "stockholders_equity": 236369000.0, "total_assets": 315624000.0, "total_liabilities": 79255000.0 }, "period_end": "2017-12-31", "ratio_units": { "leverage": "ratio", "revenue_growth_yoy": "ratio" }, "ratios": { "leverage": 0.33530200660831155, "revenue_growth_yoy": 0.8778367226643089 } }, { "accn": "0001047469-20-001809", "filed": "2020-03-26", "fiscal_year": 2016, "form": "10-K", "fundamental_units": { "capex": "USD", "cash": "USD", "free_cash_flow": "USD", "operating_cash_flow": "USD", "operating_income": "USD", "revenue": "USD", "stockholders_equity": "USD", "total_assets": "USD", "total_liabilities": "USD" }, "fundamentals": { "capex": 2751000.0, "cash": 42461000.0, "free_cash_flow": -115787000.0, "operating_cash_flow": -113036000.0, "operating_income": -132916000.0, "revenue": 6786000.0, "stockholders_equity": 265431000.0, "total_assets": 383358000.0, "total_liabilities": 117927000.0 }, "period_end": "2016-12-31", "ratio_units": { "leverage": "ratio" }, "ratios": { "leverage": 0.444284955412141 } } ], "latest_filing": { "accn": "0001104659-26-019652", "filed": "2026-02-25", "form": "10-K" }, "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.", "schema_version": "1", "sic": "2835", "sic_description": "In Vitro & In Vivo Diagnostic Substances", "source_urls": { "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000744218.json", "sec_submissions": "https://data.sec.gov/submissions/CIK0000744218.json" }, "ticker": "CLDX" }